C2N Diagnostics turns Alzheimer's diagnosis into a minimally invasive procedure
C2N Diagnostics' PrecivityAD and PrecivityAD2 tests detect amyloid and tau biomarkers. Japanese regulators approved these blood-based methods for early Alzheimer's diagnosis.
- Field
- medicine and diagnostics
- What they did
- C2N Diagnostics developed blood tests that measure specific protein biomarkers to enable early detection of Alzheimer's disease.
- Why it matters
- This approach offers a minimally invasive alternative to procedures like spinal taps or MRI scans, making diagnosis more accessible for patients.
#alzheimer's#biomarker#diagnosis#japan#precision medicine



